sucl-1 Antibody

What is SUCL-1 antibody and what biological functions does it target?

SUCL-1 antibody (also known as SUCLG1 antibody) targets the alpha subunit of succinyl-CoA ligase, an essential enzyme in the citric acid cycle. This protein is encoded by the SUCLG1 gene and functions in mitochondrial metabolism, catalyzing the ATP- or GTP-dependent ligation of succinate and CoA to form succinyl-CoA . The enzyme plays a critical role in energy production within cells, and defects in SUCLG1 have been associated with mitochondrial DNA depletion syndrome .

SUCL-1/SUCLG1 is part of a protein family that includes related enzymes like SUCLA2, which encodes the ATP-forming β subunit of succinyl-CoA ligase. Together, these proteins form functional complexes that are vital for cellular metabolism, particularly in tissues with high energy demands such as the brain and muscle .

What are the primary research applications for SUCL-1 antibody?

Based on validated applications, SUCL-1/SUCLG1 antibodies are primarily used in:

These applications enable researchers to study SUCL-1/SUCLG1 expression levels, tissue distribution, and potential alterations in disease states . The antibody has demonstrated consistent reactivity across human, mouse, and rat samples, making it versatile for comparative studies across species .

How should researchers validate SUCL-1 antibody before experimental use?

Proper antibody validation is essential for generating reliable research data. For SUCL-1 antibody, implement the following validation strategy:

• Controls verification: Use both positive and negative controls in every experiment. For SUCL-1, HepG2 cells and rat liver tissue serve as reliable positive controls for western blotting . For negative controls, consider cell lines known to have low or no expression of SUCL-1, or use genetic knockdown/knockout models if available.

• Specificity testing: Verify specificity by observing a single band at the expected molecular weight (approximately 35 kDa for SUCL-1/SUCLG1) . Multiple bands may indicate lack of specificity or post-translational modifications.

• Cross-reactivity assessment: If studying specific species, ensure the antibody has been validated for that species. Current data shows SUCLG1 antibody effectively detects human, mouse, and rat targets .

• Methodology-specific validation: Different applications require different validation approaches. For immunohistochemistry with SUCL-1 antibody, antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0 is recommended .

• Literature verification: Review published data that used the same antibody clone/lot for similar applications, focusing on studies showing full blots and proper controls .

For Western Blotting:

• Prepare tissue or cell lysates using a buffer containing protease inhibitors to prevent degradation

• Recommended dilution range: 1:5000-1:10000

• Load appropriate protein amounts (typically 20-50 μg per lane)

• Include positive controls (HepG2 cells or rat liver tissue)

For Immunohistochemistry:

• Fixation: Formalin-fixed, paraffin-embedded tissues are suitable

• Antigen retrieval: Use TE buffer pH 9.0 (preferred) or citrate buffer pH 6.0

• Recommended dilution range: 1:50-1:500

• Include positive control tissues (mouse kidney or human liver cancer tissue)

For Immunoprecipitation:

• Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

• Verify successful IP through western blot analysis

• Mouse kidney tissue has been validated as an appropriate positive control

How can researchers address inconsistent SUCL-1 antibody staining in immunohistochemistry applications?

Inconsistent staining with SUCL-1 antibody may result from several factors. Address these methodically:

• Optimize antigen retrieval: SUCLG1 antibody requires specific antigen retrieval conditions. If experiencing weak or inconsistent staining, experiment with both recommended buffers (TE buffer pH 9.0 and citrate buffer pH 6.0) and vary retrieval times.

• Adjust antibody concentration: Titrate the antibody concentration within the recommended range (1:50-1:500) . Start with a middle dilution and adjust based on signal strength.

• Control for tissue fixation variables: Overfixation can mask epitopes. Standardize fixation protocols and consider testing frozen sections if persistent problems occur with fixed samples.

• Verify subcellular localization: SUCL-1/SUCLG1 is a mitochondrial protein that shows distinct localization patterns. In properly stained samples, co-localization with mitochondrial markers such as the δ subunit of the mitochondrial F0–F1 ATP synthase should be observed .

• Confirm cell-type specificity: In human brain tissue, SUCL-1/SUCLG1 shows exclusive neuronal expression and is absent in glial cells. If observing different patterns, antibody specificity should be carefully re-evaluated .

What considerations are important when interpreting SUCL-1 antibody western blot results?

When analyzing western blot data for SUCL-1/SUCLG1:

• Molecular weight verification: Confirm signal at approximately 35 kDa, which is the expected molecular weight for SUCLG1 .

• Band specificity assessment: A single band at the expected molecular weight suggests specificity. Multiple bands may indicate:

  • Non-specific binding

  • Protein degradation (smaller fragments)

  • Post-translational modifications

  • Splice variants

• Quantitative analysis considerations: When performing densitometry:

  • Use appropriate loading controls (beta-actin, GAPDH, etc.)

  • Ensure signal is within linear detection range

  • Normalize to total protein load when comparing expression across different tissues

• Cross-experiment comparability: For comparative studies, process all samples simultaneously under identical conditions to minimize technical variability.

How does SUCL-1 antibody performance compare in studies of disease models versus normal tissues?

When using SUCL-1 antibody in disease-related research, several important considerations emerge:

• Expression level variations: SUCLG1 expression may change in disease states. For example, defects in SUCLG1 are associated with mitochondrial DNA depletion syndrome, which could affect antibody performance due to significantly reduced target presence .

• Cross-reactivity in pathological tissues: Increased background can occur in diseased tissues due to:

  • Increased tissue autofluorescence/autoperoxidase activity

  • Non-specific binding to damaged tissue components

  • Altered protein conformation affecting epitope accessibility

• Control selection for disease studies: When studying SUCL-1 in disease models:

  • Include both normal and diseased tissues from the same subject when possible

  • Consider using tissue microarrays (TMAs) with variable expression levels for quality control

  • Employ cell lines with known SUCLG1 expression levels as reference standards

• Compensatory protein expression: In some mitochondrial disorders, compensatory upregulation of related proteins may occur. For example, SUCLG2 (encoding the GTP-forming β subunit) might show altered expression in conditions affecting SUCLG1 .

What are the critical considerations when using SUCL-1 antibody for mitochondrial localization studies?

SUCL-1/SUCLG1 is a mitochondrial protein with specific localization patterns that vary across tissues. For optimal mitochondrial localization studies:

• Co-localization verification: Always perform co-staining with established mitochondrial markers. Studies have shown almost complete co-localization (>99%) of SUCL-1/SUCLG1 with the δ subunit of the mitochondrial F0–F1 ATP synthase .

• Cell-type specificity awareness: In human brain tissue, SUCL-1/SUCLG1 shows exclusive neuronal expression, with immunoreactivity absent in glial cells (identified by GFAP and S100 markers) . This distinct cell-type distribution must be considered when interpreting results.

• Fixation and permeabilization optimization: For mitochondrial proteins:

  • Use freshly prepared 4% paraformaldehyde for optimal fixation

  • Employ appropriate permeabilization (0.1-0.3% Triton X-100) to allow antibody access to mitochondrial targets

  • Consider mild fixation conditions to preserve mitochondrial morphology

• Tissue-specific expression patterns: SUCL-1 antibody shows distinct distribution patterns across tissues. For example, radiolabeled antibodies against related mitochondrial markers demonstrate high uptake in spleen and liver, with autoradiography confirming localization to macrophage-containing regions in these tissues .

How can researchers integrate SUCL-1 antibody with advanced structural biology approaches?

Recent advances in structural biology offer opportunities to enhance SUCL-1 antibody research:

What are the best practices for reporting SUCL-1 antibody methodologies in publications?

To enhance reproducibility and transparency when publishing research utilizing SUCL-1 antibody:

• Comprehensive antibody reporting: Include the following details :

  • Complete antibody identifier (catalog number, clone ID, lot number)

  • Source/vendor information

  • Species and clonality (e.g., rabbit polyclonal)

  • Concentration/dilution used for each application

  • RRID (Research Resource Identifier) when available (e.g., AB_2197177 for SUCLG1 antibody)

• Validation evidence inclusion: Describe the validation steps performed:

  • Positive and negative controls used

  • Specificity verification methods

  • Reference to previous validation if relying on established antibodies

• Detailed methodological reporting: For each application, provide:

  • Complete protocol details (buffers, incubation times, temperatures)

  • Image acquisition parameters

  • Quantification methods with statistical approaches

• Control experiment documentation: Always include images of control experiments:

  • Show full western blots rather than cropped versions

  • Include positive and negative control tissues in IHC figures

  • Document antibody performance in appropriate knockout or knockdown models when available

• Data availability: Consider depositing raw image data in appropriate repositories to enhance transparency and reproducibility.

How should researchers address contradictory results when using SUCL-1 antibody compared to published literature?

When encountering discrepancies between your SUCL-1 antibody results and published findings:

• Methodological differences assessment: Carefully compare:

  • Antibody source, clone, and lot number

  • Protocol differences (buffers, incubation conditions)

  • Sample preparation methods

  • Detection systems and sensitivity

• Biological variability considerations:

  • Different cell lines or tissue sources may have variable SUCL-1 expression

  • Disease states can alter expression patterns

  • Species differences may affect antibody performance

• Validation approach for contradictory findings:

  • Use multiple antibodies targeting different epitopes of SUCL-1

  • Employ orthogonal techniques (mRNA quantification, mass spectrometry)

  • Consider genetic approaches (overexpression, knockdown) to confirm specificity

• Transparent reporting of discrepancies: When publishing:

  • Clearly acknowledge contradictions with previous literature

  • Provide potential explanations for differences

  • Include all validation evidence supporting your findings

• Contact previous authors: If struggling with published antibody results, contact the authors who may provide valuable troubleshooting information .